Questions aim low, answers land high: the dialogue keeps correcting expectations upward with facts already in hand
The model's full reasoning — Q3 2016 call → NOThe question asks whether there is a recurring mismatch in level between what questioners assume and what management reports, with the mismatch running upward. I need to analyze the Q&A portion of the call. Let me review the exchanges: 1. Ken Cacciatore asks about litigation update on Trokendi XR - this is a neutral question, not really framed around caution. Management says no trial date yet, likely shifting to next year, but confident in IP. 2. Annabel Samimy asks about SPN-810 enrollment - whether the type/severity of patients changed and retention rates. This is a question about a clinical trial that has had enrollment challenges. Management explains the changes are about caregiver compliance with diaries, not patient profile. Management says enrollment continues into 2017, data likely 2018. This is not really an upward correction - management is acknowledging slower enrollment. 3. Annabel Samimy asks about 812 - whether they'd try higher doses. Management says it's a possibility, discussing with FDA. This is not really a mismatch either. 4. David Amsellem asks about gross-to-nets for next year - management says similar to current levels. Neutral. 5. David Amsellem asks about BD - whether enrollment issues change calculus on adding assets. Management says 812 may accelerate ahead of 810, but this is speculative. 6. John Boris asks about Orenitram royalty, Shire drug royalty rate, and wholesaler de-stocking. Management says not providing guidance on royalties, low single digit for Shire, and not aware of de-stocking. Looking at the overall call, the questions don't seem to be consistently framed below the business. The questions are fairly routine - about litigation, enrollment, gross-to-nets, BD strategy, royalties. Management doesn't repeatedly correct upward with concrete facts. The enrollment question is actually about a known challenge (slow enrollment), and management acknowledges it continues into 2017. The one area where there's some positive news is the 812 Phase 2b results, but that was announced in October (before this call) and management discusses it as a possibility for higher doses, not as a correction of a cautious frame. The questions don't seem to sit below the business in a recurring way. They're standard analyst questions about various aspects of the business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| BHF | Brighthouse Financial, Inc. | Q1 2022 | 2022-05-10 | C |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| TMHC | Taylor Morrison Home Corporation | Q2 2018 | 2018-08-01 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| KRG | Kite Realty Group Trust | Q1 2018 | 2018-04-26 | C+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DHR | Danaher Corporation | Q1 2017 | 2017-04-20 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GOGO · Q1 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with things already happening. YES The analysts' questions repeatedly frame the business around cautious or risk-oriented assumptions—such as ARPA trajectory concerns amid competition, cash and liquidity needs, potential sentiment issues with the Gogo brand, and competitive pressures from Panasonic—while management consistently corrects upward by citing concrete, already-realized facts: record revenues, 2Ku now in service on AeroMexico and IAG, over 1,000 planes awarded, Delta increases, install records, and backlog progress already achieved. This pattern repeats across multiple exchanges, with management pointing to present-tense operational realities that exceed the cautious premises embedded in the questions.
LAUR · Q1 2018 → YESThe question is about whether there's a clear, recurring mismatch in level between what the questioners assume and what management reports, with the mismatch running UPWARD. Analysts think more modest...YES The transcript shows a clear recurring mismatch running upward. Analysts repeatedly probe cautious angles—Chile as a potential end rather than final ruling, Brazil FIES exposure as a risk, margin phasing and guidance including divestitures, Turkey as needing update, FCF not raised despite Chile, leverage post-St. Augustine, and Accelerator 2.0 health sciences—framing the business around lingering uncertainties or modest upside.
JHX · Q3 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with concrete things already happening. ...NO The transcript shows analysts probing for signs of weakness or slowdowns (seasonal margins, destocking, Europe performance, PDG pickup, volumes vs targets), but management repeatedly corrects upward with concrete current facts: strong Q3 margins (2.6 points better), no destocking, plants running well, costs controlled, 12% volume growth, Europe already through the one-off, and inventory normalized.